Pharma BD Deal Intelligence
Bayer's $63B all-cash bet to become the world's biggest agrochem player instead detonated into its defining catastrophe: Roundup litigation racked up $20B+ in settlements and $12.9B in write-downs, erasing roughly 70% of Bayer's market cap—a deal that "Failed to Achieve" its promise.
Roundup litigation cost $20B+ settlements, $12.9B write-downs, 70% market cap destroyed
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Frankfurt School professor Michael Grote noted larger and more diversified firms are valued less than specialized firms, describing the deal as on the negative…
Bayer bids $66 billion for Monsanto in the largest acquisition of 2016 in any sector, offering a 44% premium to Monsantos share price before takeover talk was…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Bayer acquired Monsanto for $63 billion ($128 per share) in an all-cash transaction, creating a global leader in agriculture and life sciences. The deal faced extensive regulatory review and required significant divestitures.
Roundup litigation cost $20B+ settlements, $12.9B write-downs, 70% market cap destroyed
Assessment window: 15yr post-close.
Bayer/Monsanto Seeds & Genomics is an agricultural-biotech transaction — seeds, traits, and crop-protection chemistries. No pharmaceutical competitive landscape applies. Relevant AgTech competitors are Corteva (DowDuPont spin-out), Syngenta (ChemChina), BASF, and Mosaic.
Bayer and Monsanto reached agreement at $128 per share after four rejected offers starting in May 2016, creating a $63 billion mega-merger in the agricultural sciences sector.
The U.S. Department of Justice conditionally approved the Bayer-Monsanto merger, requiring Bayer to divest $9 billion in businesses generating EUR 2.2 billion in annual sales revenue.
Bayer completed its $63 billion acquisition of Monsanto, the largest deal in Bayer history, creating a global leader in agriculture with combined crop science and digital farming capabilities.
Bayer announced agreements to pay $10.1-10.9 billion to resolve approximately 125,000 filed and unfiled Roundup cancer claims, one of the largest mass tort settlements in corporate history.
Bayer has recorded cumulative goodwill impairments of EUR 12.9 billion on the Crop Science division since the 2018 Monsanto acquisition, reflecting persistent litigation and business headwinds.
A Missouri state court judge granted preliminary approval to a $7.25 billion Roundup class-action settlement to resolve approximately 65,000 remaining cancer lawsuits against Bayer.
Monsanto acquisition is widely ranked among the worst M&A deals ever. Roundup litigation cost Bayer $20B+ in settlements, $12.9B in write-downs, and roughly 70% of its market cap.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Monsanto Company (this deal) | 2016 | $63.0B | 35 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2016 deals · Bayer AG deals · Multiple (undisclosed) deals